Navigation Links
Raptor Pharmaceutical Corp. Announces Closing of $7.5 Million Registered Direct Offering
Date:12/23/2009

ated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that the proceeds from this offering will enable us to move all of our principal clinical programs forward; that we will execute our pivotal Phase 3 clinical trial for cystinosis in 2010, if at all; that we will work to achieve our next clinical milestones and move closer to potential commercialization; and that any of Raptor's clinical and preclinical drug candidates will result in approved therapeutics. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent the Company's forward looking statements from fruition include: that Raptor may be unsuccessful at raising funds to continue its development programs; Raptor may be unsuccessful in developing any products or acquiring products; that Raptor's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develo
'/>"/>

SOURCE Raptor Pharmaceutical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Raptor Pharmaceutical Corp. Announces $7.5 Million Securities Offering
2. Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
3. Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis
4. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
5. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
6. Raptor Pharmaceutical Expands Board of Directors
7. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
8. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... June 30, 2014. Quarter Ended June ... 30, 2014 increased $492,000, or 18%, to $3.2 million ... 30, 2013, due primarily to an increase of $746,000 ... Company,s largest customer, partially offset by an aggregate decrease ...
(Date:9/18/2014)... Texas , Sept. 18, 2014  Casen Buswell has ... and muscles to harden.  His case is one of only ... the world.  The only hospital in the United ... the world, offering treatment with the dual wave-length laser, is ... San Antonio . Using a laser available in ...
(Date:9/18/2014)... PHILADELPHIA and LONDON ... new era for biopharmaceutical companies. Competition for innovation, ... necessity to keep up with the fast-changing environment ... also influence clinical trials, and clinical trial costs ... effective patient recruitment. Studies conducted by ...
Breaking Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3
... from a Phase III,clinical trial evaluating the efficacy ... the treatment of postmenopausal osteoporosis were,presented at the ... Annual Meeting. In the non-inferiority study comparing risedronate ... [Actonel(R) (risedronate sodium,tablets)] increases in bone mineral density ...
... Medical,Technologies, Inc. (Nasdaq: RMTI ), a ... specialty pharmaceuticals focused on the end-,stage-renal-disease market ... in its Phase IIb dose-ranging study for ... drug. The Phase IIb dose-ranging study ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
(Date:9/18/2014)... 2014 Reduce bags under the eyes, ... for these issues in a serum. , "Our Face ... says Kathy Heshelow, founder of Sublime Beauty®. "Each works ... collagen, to improve the eye area." , Today ... wrinkles, dark circles and bags at Amazon with coupon ...
(Date:9/18/2014)... September 18, 2014 Kent, WA Chiropractor ... Chiropractic are pleased to announce that Dawn Kelly has agreed ... Dr. Saggau looks forward to Ms. Kelly expanding her ... talents will make her a key contributor. “ Dawn ... educational, professional, and personal experiences that will allow me ...
(Date:9/18/2014)... 2014 Alexandria, VA — The ... 10 more communities have joined the growing ranks of ... accreditation. The decisions bring the number of governmental public ... is the non-profit organization that administers the national public ... the health of the public by advancing the quality ...
(Date:9/18/2014)... (HealthDay News) -- Older people become more physically vulnerable ... balance of stress hormones during bereavement changes with age, ... are grieving are more likely to have weakened immune ... the difficult weeks and months after loss, we can ... abundant type of white blood cell and as such ...
(Date:9/18/2014)... 2014 It’s been just a few short ... pending bunion splint to website visitors, but already the response ... was absolutely delighted. It is perfect and I find it ... them. THANK YOU FOR LISTENING!!!" Another user compared the ... hole used to slip to the end of my toe. ...
Breaking Medicine News(10 mins):Health News:The Secret to Improving Under-Eye Skin: 30% Off Sale and Report on Ingredients Ends Tonight on the Face Whisperer® Advanced Eye Gel 2Health News:Lake Meridian Chiropractic of Kent, WA Announces that Dawn Kelly Has Been Promoted to the Position of Office Manager 2Health News:Ten More Communities Reaping Benefits of National Accreditation 2Health News:Ten More Communities Reaping Benefits of National Accreditation 3Health News:Ten More Communities Reaping Benefits of National Accreditation 4Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3
... taking too much supplemental calcium are on the rise, ... of the Journal of the American Society Nephrology ... calcium-alkali syndrome is growing in large part because of ... The milk-alkali syndrome arose in the early 1900s ...
... rural southern Asia are exposed every day to unsafe levels ... doubles their risks for cancer, causes cardiovascular disease, and inhibits ... The World Health Organization (WHO) has referred to the situation ... as "the largest mass poisoning of a population in history." ...
... Experts are now recommending that low-dose aspirin therapy to prevent ... younger than 50 and women younger than 60, who have ... aspirin. The new recommendations are based on an analysis ... side effects such as stomach bleeding, and to a much ...
... found if young adults were more fit, 34% of high ... (HealthDay News) -- Low levels of physical activity and fitness ... 20-year study of young adults shows. , The study, released ... print issue of the journal Hypertension , found that ...
... to play in disease detection , TUESDAY, June 1 (HealthDay ... signs of prostate cancer in human urine, adding to the ... friend. , Some scientists have questioned similar reports of dogs ... lead author of this latest study said the findings are ...
... patients who,ve been told to rest and avoid exercise can ... both during and after treatment, according to new national guidelines. ... Biostatistics and a member of the Abramson Cancer Center at ... guidelines at an educational session at the 2010 meeting of ...
Cached Medicine News:Health News:Calcium supplements: too much of a good thing? 2Health News:Researchers offer solutions to poisonous well-water crisis in southern Asia 2Health News:Researchers offer solutions to poisonous well-water crisis in southern Asia 3Health News:Aspirin recommendations changed for many younger diabetic patients 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 3Health News:Dog Sniffs Out Prostate Cancer in Small Study 2Health News:New cancer guidelines: Exercise during and after treatment is now encouraged 2Health News:New cancer guidelines: Exercise during and after treatment is now encouraged 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: